Sign in
Taking people in United StatesNo phase

Electronic Alert to Check Liver Scarring in Primary Care Patients

Tests an electronic health record alert for liver scarring in adults with fatty liver.

Key facts

Who runs it
Medical University of South Carolina
Where
Charleston, United StatesSee the site
Trial code
Registry title
Advanced Fibrosis Detection for MASLD in Primary Care
Status
Recruiting
People taking part
225 people, planned
Started
16 Mar 2026
Expected to end
Sept 2030
Type of study
Interventional, 5 groups
Treatments tested
  • EHR alert
Record updated
31 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults in primary care who have a diagnosis of MASLD (a fatty liver disease linked to metabolic problems). Primary care clinicians also take part and give feedback.

Age
18 years or older
Sex
All sexes can join
Disease stage
A diagnosis code for MASLD. People with cirrhosis or its complications cannot join.

Main reasons for not taking part

  • Cirrhosis
  • Complications of cirrhosis, such as portal hypertension or hepatic encephalopathy
  • Hepatocellular carcinoma
  • Previous liver transplant
  • Pregnant women

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Patients with a diagnosis code for MASLD
  • Type 2 diabetes mellitus will
  • All physicians, physician assistants, and nurse practitioners delivering primary care during the intervention phase of the study

Who cannot take part

  • All patients with cirrhosis, complications of cirrhosis (e.g. portal hypertension, hepatic encephalopathy), hepatocellular carcinoma, or previous liver transplant will be excluded
  • pregnant women; Clinicians Clinicians will also be study participants, as we will be surveying them for feedback on the MASLD fibrosis risk assessment intervention. The MUSC primary care network at last count employed 122 clinicians across the 27 primary care practices
  • None

Other criteria

  • Patients

Where in United States

  • Medical University of South CarolinaCharleston, United StatesContact: Chloe Bays, MPHTaking people

About the trial

What the trial wants to find out

This proposal evaluates the implementation of a novel, non-interruptive, electronic health record alert for metabolic dysfunction-associated steatotic liver disease (MASLD) fibrosis risk assessment in primary care patients with MASLD using a stepped wedge, cluster randomized design. This work will generate generalizable data to dramatically enhance MASLD management in primary care.

The 5 groups in the trial

  • Month 6Treatment being tested

    All clinics will begin the study in the control phase. The intervention will be introduced in 5 steps with 5-6 clinics per step at intervals of 6 months. The transition phase from the control period to the intervention period will last 1 month and provide time for rolling out educational content and access to the MASLD fibrosis risk assessment EHR alert. A computer-generated randomization program will assign clinics to one of the 5 pre-defined transition steps (months 6, 12, 18, 24, and 30).

    Treatment: EHR alert

  • Month 12Treatment being tested

    All clinics will begin the study in the control phase. The intervention will be introduced in 5 steps with 5-6 clinics per step at intervals of 6 months. The transition phase from the control period to the intervention period will last 1 month and provide time for rolling out educational content and access to the MASLD fibrosis risk assessment EHR alert. A computer-generated randomization program will assign clinics to one of the 5 pre-defined transition steps (months 6, 12, 18, 24, and 30).

    Treatment: EHR alert

  • Month 18Treatment being tested

    All clinics will begin the study in the control phase. The intervention will be introduced in 5 steps with 5-6 clinics per step at intervals of 6 months. The transition phase from the control period to the intervention period will last 1 month and provide time for rolling out educational content and access to the MASLD fibrosis risk assessment EHR alert. A computer-generated randomization program will assign clinics to one of the 5 pre-defined transition steps (months 6, 12, 18, 24, and 30).

    Treatment: EHR alert

  • Month 24Treatment being tested

    All clinics will begin the study in the control phase. The intervention will be introduced in 5 steps with 5-6 clinics per step at intervals of 6 months. The transition phase from the control period to the intervention period will last 1 month and provide time for rolling out educational content and access to the MASLD fibrosis risk assessment EHR alert. A computer-generated randomization program will assign clinics to one of the 5 pre-defined transition steps (months 6, 12, 18, 24, and 30).

    Treatment: EHR alert

  • Month 30Treatment being tested

    All clinics will begin the study in the control phase. The intervention will be introduced in 5 steps with 5-6 clinics per step at intervals of 6 months. The transition phase from the control period to the intervention period will last 1 month and provide time for rolling out educational content and access to the MASLD fibrosis risk assessment EHR alert. A computer-generated randomization program will assign clinics to one of the 5 pre-defined transition steps (months 6, 12, 18, 24, and 30).

    Treatment: EHR alert

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Primary Care
Plain-language title
Electronic Alert to Check Liver Scarring in Primary Care PatientsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
31 March 2026